Physician profile
Lynn S Lee
NPI 1548298839
$2,132.40
in general payments reported to CMS, 2019-2025
29 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $317 · 2021: $332 · 2022: $238 · 2023: $70.38 · 2024: $275 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $369.83 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $260.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $179.83 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $166.82 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $157.74 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $113.26 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.56 | 2024-2025 | |
| Abbvie INC. | $82.94 | 2020-2022 | |
| Amgen INC. | $78.15 | 2019-2024 | Repatha, Otezla |
| Genzyme Corporation | $70.00 | 2019 | |
| Abbott Laboratories | $69.49 | 2019-2024 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $60.35 | 2021-2022 | |
| Orthofix Medical, INC. | $56.15 | 2025 | Spinal-Stim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.42 | 2020-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $39.38 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $37.76 | 2019-2021 | |
| Glaxosmithkline, LLC. | $36.84 | 2024-2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $26.07 | 2019 | |
| Axsome Therapeutics, INC. | $23.09 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.71 | 2024 | Xifaxan |
| Evoke Pharma, INC. | $21.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.63 | 2020 | |
| Amarin Pharma, INC. | $19.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.00 | 2019 | |
| Redhill Biopharma INC. | $17.67 | 2021 | |
| Janssen Biotech, INC. | $13.89 | 2021 | |
| Valeritas, INC. | $13.33 | 2019 | |
| Merck Sharp & Dohme LLC | $13.14 | 2019 | |
| Vifor Pharma, INC. | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.